terfenadine has been researched along with Cardiotoxicity in 3 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiotoxicity is caused mainly by the inhibition of human ether-a-go-go related gene (hERG) channel protein." | 1.72 | Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity. ( Jani, V; Joshi, R; Kamboj, R; Koulgi, S; Nair, V; Palle, V; Phukan, S; Saini, JS; Sonavane, U, 2022) |
| " Integration of metabolic function in toxicology models can improve adverse effects prediction in preclinical studies and this system could also be used for chronic studies as well." | 1.48 | Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system. ( Bridges, LR; Carmona-Moran, CA; Ekman, G; Elbrecht, DH; Hickman, JJ; Jackson, M; Kumanchik, L; Langer, J; Lavado, A; Long, CJ; Martin, C; McAleer, CW; Narasimhan, NS; Note, R; Oleaga, C; Persaud, K; Riu, A; Roles, J; Rothemund, S; Sasserath, T; Schnepper, MT; Teissier, S; Tran, M; Wang, YI, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Koulgi, S | 1 |
| Jani, V | 1 |
| Nair, V | 1 |
| Saini, JS | 1 |
| Phukan, S | 1 |
| Sonavane, U | 1 |
| Joshi, R | 1 |
| Kamboj, R | 1 |
| Palle, V | 1 |
| Oleaga, C | 1 |
| Riu, A | 1 |
| Rothemund, S | 1 |
| Lavado, A | 1 |
| McAleer, CW | 1 |
| Long, CJ | 1 |
| Persaud, K | 1 |
| Narasimhan, NS | 1 |
| Tran, M | 1 |
| Roles, J | 1 |
| Carmona-Moran, CA | 1 |
| Sasserath, T | 1 |
| Elbrecht, DH | 1 |
| Kumanchik, L | 1 |
| Bridges, LR | 1 |
| Martin, C | 1 |
| Schnepper, MT | 1 |
| Ekman, G | 1 |
| Jackson, M | 1 |
| Wang, YI | 1 |
| Note, R | 1 |
| Langer, J | 1 |
| Teissier, S | 1 |
| Hickman, JJ | 1 |
| Bobesh, KA | 1 |
| Renuka, J | 1 |
| Srilakshmi, RR | 1 |
| Yellanki, S | 1 |
| Kulkarni, P | 1 |
| Yogeeswari, P | 1 |
| Sriram, D | 1 |
3 other studies available for terfenadine and Cardiotoxicity
| Article | Year |
|---|---|
Molecular dynamics of hERG channel: insights into understanding the binding of small molecules for detuning cardiotoxicity.
Topics: Cardiotoxicity; Ether-A-Go-Go Potassium Channels; Humans; Ligands; Molecular Dynamics Simulation; Po | 2022 |
Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.
Topics: Cardiotoxicity; Cell Line; Cells, Cultured; Coculture Techniques; Cyclophosphamide; Drug Evaluation, | 2018 |
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
Topics: Animals; Antitubercular Agents; Atrioventricular Block; Cardiotoxicity; DNA Gyrase; Enzyme Assays; E | 2016 |